Deutsche Bank AG Buys 360 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Deutsche Bank AG raised its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 6.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,284 shares of the company’s stock after acquiring an additional 360 shares during the quarter. Deutsche Bank AG’s holdings in Inspire Medical Systems were worth $1,165,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INSP. First Horizon Advisors Inc. raised its stake in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 124 shares during the last quarter. Huntington National Bank increased its holdings in shares of Inspire Medical Systems by 228.3% in the fourth quarter. Huntington National Bank now owns 174 shares of the company’s stock valued at $32,000 after purchasing an additional 121 shares in the last quarter. Harbour Investments Inc. increased its holdings in shares of Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after purchasing an additional 99 shares in the last quarter. AlphaQuest LLC raised its position in Inspire Medical Systems by 7,275.0% in the 4th quarter. AlphaQuest LLC now owns 295 shares of the company’s stock worth $55,000 after purchasing an additional 291 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Inspire Medical Systems by 61.9% during the 4th quarter. Quadrant Capital Group LLC now owns 327 shares of the company’s stock worth $61,000 after buying an additional 125 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

INSP has been the topic of a number of research reports. Royal Bank of Canada cut their target price on shares of Inspire Medical Systems from $260.00 to $215.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 15th. Piper Sandler dropped their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. JPMorgan Chase & Co. cut their price objective on shares of Inspire Medical Systems from $235.00 to $195.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a “hold” rating on the stock in a research note on Monday, April 21st. Finally, Morgan Stanley dropped their target price on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $211.91.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $143.24 on Monday. The company has a market capitalization of $4.22 billion, a PE ratio of 82.80, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $225.00. The company has a 50-day simple moving average of $153.92 and a 200 day simple moving average of $174.83.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, May 5th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.33. The business had revenue of $201.32 million for the quarter, compared to the consensus estimate of $194.89 million. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The company’s revenue was up 22.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.34) earnings per share. As a group, analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the company’s stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $160.00, for a total value of $57,600.00. Following the transaction, the director now owns 24,046 shares of the company’s stock, valued at $3,847,360. This represents a 1.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.10% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.